Tvardi Therapeutics (LTS:0HTC) Other Current Liabilities : £0.47 Mil (As of Mar. 2025)

View and export this data going back to 2025. Start your Free Trial

What is Tvardi Therapeutics Other Current Liabilities?

Tvardi Therapeutics's other current liabilities for the quarter that ended in Mar. 2025 was £0.47 Mil.

Tvardi Therapeutics's quarterly other current liabilities increased from Mar. 2024 (£0.00 Mil) to Sep. 2024 (£0.90 Mil) but then declined from Sep. 2024 (£0.90 Mil) to Mar. 2025 (£0.47 Mil).

Tvardi Therapeutics's annual other current liabilities increased from . 20 (£0.00 Mil) to Dec. 2022 (£0.56 Mil) and increased from Dec. 2022 (£0.56 Mil) to Dec. 2023 (£0.75 Mil).

Tvardi Therapeutics Other Current Liabilities Historical Data

The historical data trend for Tvardi Therapeutics's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tvardi Therapeutics Other Current Liabilities Chart

Tvardi Therapeutics Annual Data

Trend

Dec22

Dec23

Other Current Liabilities

0.56

0.75

Tvardi Therapeutics Quarterly Data
	Dec22	Dec23	Mar24	Sep24	Mar25
Other Current Liabilities	0.56	0.75	-	0.90	0.47

Tvardi Therapeutics Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

Tvardi Therapeutics Other Current Liabilities Related Terms

Thank you for viewing the detailed overview of Tvardi Therapeutics's Other Current Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Tvardi Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tvardi Therapeutics Inc (LTS:0HTC) » Definitions » Other Current Liabilities

Comparable Companies

Traded in Other Exchanges

TVRD:USA 69C:Germany

Address

3 Sugar Creek Center boulevard, Suite 525, Sugar Land, TX, USA, 77478

Website

Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.

Tvardi Therapeutics Headlines

No Headlines